Chronic Myelogenous Leukemia Treatment Market To Touch US$ 8,550.8 Mn By 2026
Increasing prevalence of chronic myelogenous leukemia in developed countries due to genetic factors is also resulting in the development of new treatment and therapies that are more effective. Researchers are also focusing on polypharmacology approach to develop the drugs that can act on multiple targets. This is leading to the drug discovery opportunities that are beyond the concept of ‘one drug, one target’. The class of drugs known as TKIs is being used on a large scale, however, side-effects of these drugs are affecting its growth. Hence, new drugs and treatments are being developed to run the treatment successfully without any risk. Moreover, the rise in the development of a combination of drug therapies is also fueling the growth of the market.
Increasing prevalence of chronic myelogenous leukemia in developed countries due to genetic factors is also resulting in the development of new treatment and therapies that are more effective. Researchers are also focusing on polypharmacology approach to develop the drugs that can act on multiple targets. This is leading to the drug discovery opportunities that are beyond the concept of ‘one drug, one target’. The class of drugs known as TKIs is being used on a large scale, however, side-effects of these drugs are affecting its growth. Hence, new drugs and treatments are being developed to run the treatment successfully without any risk. Moreover, the rise in the development of a combination of drug therapies is also fueling the growth of the market.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Global <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong>: Segmental Highlights and Table of<br />
Content (2017 – <strong>2026</strong>)<br />
Global <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong>: New Class of Drugs to Transform<br />
<strong>Treatment</strong> of CML, observes TMR<br />
As per the latest report by Transparency <strong>Market</strong> Research (TMR), the global chronic myelogenous<br />
leukemia market is expected to witness strong growth. The market is estimated to register 6.7%<br />
CAGR during the forecast period 2017-<strong>2026</strong>. It is also expected to reach <strong>US$</strong> 8,<strong>550.8</strong> million<br />
revenue by the end of <strong>2026</strong>.<br />
Report overview @ https://www.transparencymarketresearch.com/chronic-myelogenous-leukemiatreatment-market.html<br />
The global <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> is segmented on the basis of type of<br />
treatment, distribution channel, drug type and region.<br />
The global chronic myelogenous leukemia treatment market has been segmented into type of<br />
treatment, distribution channel, drug type and region. On the basis of treatment type, the segment<br />
includes disease specific treatment and symptomatic treatment. On the basis of drug type, the<br />
segment includes branded, and generic. On the basis of the distribution channel, the market is<br />
segmented into hospital pharmacies, specialty pharmacies, and retail pharmacies.<br />
Geographically, the global chronic myelogenous leukemia treatment market is segmented into<br />
North America, Europe, Latin America, Asia Pacific Excluding Japan (APEJ), Japan, and the<br />
Middle East and Africa (MEA). The report segmentation includes country-wise analysis on the<br />
major parameters of the market. The forecast for each region, drug type, treatment type and<br />
distribution channel has been provided for the year 2017-<strong>2026</strong>. The CAGR in form of percentage<br />
and revenue share for each segment is included in the report.<br />
Based on the distribution channel, the market is categorized into specialty pharmacies, hospital<br />
pharmacies, and retail pharmacies. Hospital pharmacies are expected to be the largest distribution<br />
channel during the forecast period 2017-<strong>2026</strong>. Region-wise, the segmentation includes North<br />
America, Latin America, Europe, Japan, Asia Pacific Excluding Japan (APEJ), and the Middle East<br />
and Africa (MEA). North America is expected to remain dominant in the global chronic<br />
myelogenous leukemia market through <strong>2026</strong>.<br />
Request A Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?<br />
flag=S&rep_id=34940<br />
Summary of Table of Content<br />
1. Global Outlook<br />
2. Global <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> - Executive Summary<br />
3. Global <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> Overview<br />
4. Global <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> Analysis and Forecast 2012-<br />
<strong>2026</strong><br />
5. North America <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> Size and Forecast, 2012-<br />
<strong>2026</strong><br />
6. Latin America <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> Size and Forecast, 2012-
<strong>2026</strong><br />
7. Europe <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> Size and Forecast, 2012-<strong>2026</strong><br />
8. Japan <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> Size and Forecast, 2012-<strong>2026</strong><br />
9. APEJ <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> Size and Forecast, 2012-<strong>2026</strong><br />
10. MEA <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> Size and Forecast, 2012-<strong>2026</strong><br />
11. Global <strong>Chronic</strong> <strong>Myelogenous</strong> <strong>Leukemia</strong> <strong>Treatment</strong> <strong>Market</strong> Competitive Landscape and<br />
Company Profile<br />
12. TMR Research Methodology<br />
13. Disclaimer and Contact information<br />
Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?<br />
rep_id=34940<ype=S<br />
About Us<br />
Transparency <strong>Market</strong> Research (TMR) is a global market intelligence company providing business<br />
information reports and services. The company’s exclusive blend of quantitative forecasting and<br />
trend analysis provides forward-looking insight for thousands of decision makers. TMR’s<br />
experienced team of analysts, researchers, and consultants use proprietary data sources and various<br />
tools and techniques to gather and analyze information.<br />
TMR’s data repository is continuously updated and revised by a team of research experts so that it<br />
always reflects the latest trends and information. With extensive research and analysis capabilities,<br />
Transparency <strong>Market</strong> Research employs rigorous primary and secondary research techniques to<br />
develop distinctive data sets and research material for business reports.<br />
Contact<br />
Transparency <strong>Market</strong> Research<br />
State <strong>To</strong>wer,<br />
90 State Street,<br />
Suite 700,<br />
Albany NY - 12207<br />
United States<br />
Tel: +1-518-618-1030<br />
USA - Canada <strong>To</strong>ll Free: 866-552-3453<br />
Sales: sales@transparencymarketresearch.com<br />
Website: https://www.transparencymarketresearch.com/<br />
Blog: http://www.tmrblog.com/
Change language